Structure-Metabolism Relationships (SMR) for the Prediction of Health Hazards by the Environmental Protection Agency. II. Application to Teratogenicity and Other Toxic Effects Caused by Aliphatic Acids

References

• Di Carlo F. J., Bickart P., Auer C. M. Role of structure-activity team (SAT) in the premanufacture notification (PMN) process. QSAR in Toxicology and Xenobiochemistry, M. Tichy. Elsevier, Amsterdam 1985; 433–449
   Google Scholar
• Di Carlo F. J., Bickart P., Auer C. M. Structure-metabolism relationships (SMR) for the prediction of health hazards by the Environmental Protection Agency. I. Background for the practice of predictive toxocilogy. Drug Metab. Rev. 1986; 17(l&2)119–132
   Google Scholar
• Di Carlo F. J. Metabolism, pharmacokinetics, and toxicokinetics defined. Drug Metab. Rev. 1982; 13: 1–4
   PubMed Web of Science ®Google Scholar
• Zubay G. Biochemistry. Addison-Wesley, Reading, MA 1983; 482
   Google Scholar
• Bruni J. Valproic acid: Review of a new antiepileptic drug. Arch. Neurol. 1979; 36: 393–398
   PubMed Web of Science ®Google Scholar
• Committee on Drugs. Valproic acid: Benefits and risks. Pediatrics 1982; 70: 316–319
   PubMed Web of Science ®Google Scholar
• Browne T. R. Drug therapy: Valproic acid. N. Engl. J. Med. 1980; 302: 661–665
   PubMed Web of Science ®Google Scholar
• Levy R. H. Valproate - modern perspectives. Epilepsia 1984; 25: S1–S77, (Levy, R. H., ed.), Suppl. 1
   Google Scholar
• Schardein J. L. Chemically Induced Birth Defects. Dekker, New York 1985; 146, 176, 468–477; 733, 740
   Google Scholar
• Nau H., Rating D., Koch S., Hauser I., Helge H. Valproic acid and its metabolites: Placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. J. Pharmacol. Exp. Ther. 1981; 219: 768–777
   PubMed Web of Science ®Google Scholar
• Koch S., Gopfert-Geyer I., Jager-Roman E., Jakob S., Huth H., Hartmann A., Rating D., Helge H. Antiepilep-tika wahrend der schwangerschaft. Dtsch. Med. Wschr. 1983; 108: 250
   PubMedGoogle Scholar
• Jager-Roman E., Deichl A., Jakob S., Hartmann A., Koch S., Rating D., Steldinger R., Nau H., Helge H. Fetal growth, major malformations and minor anomalies in infants born to women receiving valproic acid. J. Pediatr, (in press)
   Web of Science ®Google Scholar
• Williams R. T. Detoxication Mechanisms, 2nd ed. Wiley, New York 1959; 60, 61, 97, 98, 727–730
   Google Scholar
• Keil W. Fats from fatty acids with odd numbers of carbon atoms: Addendum to VI. Z. Physiol. Chem. 1947; 282: 137–142, Chem. Abstr., 43, 6163 (1949)
   Google Scholar
• Whyte D. D. Triglyceride esters of a-branched carboxylic acids. U.S. Pat. 3,579,548, May 18, 1971
   Google Scholar
• Jandacek R. J. The effect of nonabsorbable lipids on the intestinal absorption of lipophiles. Drug Metab. Rev. 1982; 13: 695–714
   PubMed Web of Science ®Google Scholar
• Gugler R., von Unruh G. E. Clinical pharmacokinetics of valproic acid. Clin. Pharmacokinet. 1980; 5: 67–83
   PubMed Web of Science ®Google Scholar
• Heinemeyer G., Nau H., Hildebrandt A. G., Roots I. Oxidation and glucuronidation of valproic acid in male rats -influence of phenobarbital, 3-methylcholanthrene, 3-naph-thoflavone and clofibrate. Biochem. Pharmacol. 1984; 34: 133–139
   Web of Science ®Google Scholar
• Granneman G. R., Wang S. I., Machinist J. M., Kesterson J. W. Aspects of the metabolism of valproic acid. Xenobiotica 1984; 14: 375–387
   PubMed Web of Science ®Google Scholar
• Morselli P. L. Antiepileptic drugs. Drug Disposition During Development, P. L. Morselli. Spectrum Publications, New York 1977; 344–346
   Google Scholar
• Bittencourt P. R. M., Perucca E., Crema A. Cerebellar toxicity of antiepileptic drugs. Neurotoxicology, K. Blum, L. Manzo. Dekker, New York 1985; 238
   Google Scholar
• Loscher W., Nau H. Pharmacological evaluation of various metabolites and analogues of valproic acid – anticonvulsant and toxic potencies in mice. Neuropharmacology 1985; 24: 427–435
   PubMed Web of Science ®Google Scholar
• Nau H., Loscher W. Valproic acid and metabolites: Pharmacological and toxicological studies. Epilepsia 1984; 25: S14–S11, Suppl. 1
   PubMed Web of Science ®Google Scholar
• Loscher W., Nau H. Valproic acid: Metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice. Arch. Int. Pharmacodyn. Ther. 1982; 257: 20–31
   PubMedGoogle Scholar
• Nau H., Loscher W. Valproic acid: Brain and plasma levels of the drug and its metabolites, anticonvulsant effects and Y-aminobutyric acid (GABA) metabolism in the mouse. J. Pharmacol. Exp. Ther. 1982; 220: 654–659
   PubMed Web of Science ®Google Scholar
• Loscher W., Nau H. Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. J. Pharmacol. Exp. Ther. 1983; 226: 845–854
   PubMed Web of Science ®Google Scholar
• Perlman B. J., Goldstein D. B. Membrane-disordering potency and anticonvulsant action of valproic acid and other short-chain fatty acids. Mol. Pharmacol. 1984; 26: 83–89
   PubMed Web of Science ®Google Scholar
• Samson F. E., Jr., Dahl N., Dahl D. R. A study on the narcotic action of short chain fatty acids. J. Clin. Invest. 1956; 35: 1291–1298
   PubMed Web of Science ®Google Scholar
• Keane P. E., Simiand J., Mendes E., Santucci V., Morre M. The effects of analogues of valproic acid on seizures induced by pentylenetetrazol and GABA content in brain of mice. Neuropharmacology 1983; 22: 875–879
   PubMed Web of Science ®Google Scholar
• Chapman A. G., Meldrum B. S., Mendes E. Acute anticonvulsant activity of structural analogues of valproic acid and changes in brain GAB A and aspartate content. Life Set 1983; 32: 2023–2031
   PubMedGoogle Scholar
• Lyon R. C., Goldstein D. B. The comparative effects of sodium valproate, sodium octanoate, and sodium valerate on spin-labeled synaptosomal plasma membranes from mouse brain. Fed. Proc 1980; 39: 1100
   Google Scholar
• Lyon R. C., Mc Comp J. A., Schreurs J., Goldstein D. B. A relationship between alcohol intoxication and the disordering of brain membranes by a series of short-chain alcohols. J. Pharmacol. Exp. Ther. 1981; 218: 669–675
   PubMed Web of Science ®Google Scholar
• Workman R. L., Jr., Swinyard E. A., Rigby D. F., Swinyard C. A. Correlation between anticonvulsant activity and plasma concentration of ethanol. J. Am. Pharm. Assoc 1958; 47: 769–772
   Google Scholar
• Swinyard E. A., Woodhead J. H. Experimental detection, quantification, and evaluation of anticonvulsants. Antiepileptic Drugs, Ed. 2, E. M. Woodbury, J. K. Penry, C. E. Pippenger. Raven Press, New York 1982; 11–126
   Google Scholar
• Rettenmeier A. W., Prickett K. S., Gordon W. R., Bjorge S. M., Chang S-L., Levy R. H., Baillie T. A. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the anti-epileptic drug valproic acid. Drug Metab. Dispos. 1985; 13: 81–96
   PubMed Web of Science ®Google Scholar
• Prickett K. S., Levy R. H., Baillie T. A. Inhibition of cytochrome P-450 by 2-n-propyl-4-pentenoic acid, a metabolite of the anticonvulsant drug valproic acid. Fed. Proc 1983; 42: 1138
   Google Scholar
• Nau H., Loscher W. Pharmacologic evaluation of various metabolites and analogs of valproic acid: Teratogenic potencies in mice. Fund. Appl. Toxicol. 1986; 6: 669–676
   PubMedGoogle Scholar
• Kao J., Brown N. A., Schmid B., Goulding E. H., Fabro S. Teratogenicity of valproic acid: In vivo and in vitro investigations. Teratogen. Carcinogen. Mutagen. 1981; 1: 367–382
   Google Scholar
• Brown N. A., Colhoun C. W. Valproic acid teratogenesis. I. In vivo /in vitro comparisons and effects on somite morphogenesis. Teratology 1984; 29: 20A–21A
   Google Scholar
• Brown N. A., Coakley M. E. Valproic acid teratogene-sis. II. Actions of related drugs and potential antagonists and the role of coenzyme A. Teratology 1984; 29: 20A
   Google Scholar
• Ortiz de Montellano P. R., Correia M. A. Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. Ann. Rev. Pharmacol. Toxicol. 1983; 23: 481–503
   PubMed Web of Science ®Google Scholar
• Prickett K. S., Baillie T. A. Evidence for the in vitro metabolism of allylisopropylacetamide to reactive intermediates: Mechanistic studies with oxygen-18. Biomed. Mass Spectrom. 1984; 11: 320–331
   PubMedGoogle Scholar
• Fong J. C., Schulz H. On the rate-determining step of fatty acid oxidation in heart: Inhibition of fatty acid oxidation by 4-pentenoic acid. J. Biol. Chem. 1978; 253: 6917–6922
   PubMed Web of Science ®Google Scholar
• Schulz H. Metabolism of 4-pentenoic acid and inhibition of thiolase by metabolites of 4-pentenoic acid. Biochemistry 1983; 22: 1827–1832
   PubMed Web of Science ®Google Scholar
• Gunstone F. D. Fatty acids. Comprehensive Organic Chemistry, D. Barton, W. D. Ollis, E. Haslam. Pergamon Press, Oxford 1979; vol. 5: 587–595
   Google Scholar
• Bodor N. Novel approaches to the design of safer drugs: Soft drugs and site-specific delivery systems. Adv. Drug Res. 1984; 13: 255–331
   Google Scholar
• Gerber N., Dickinson R. G., Harland R. C., Lynn R. K., Houghton D., Antonias J. I., Schimschock J. C. Reye-like syndrome associated with valproic acid therapy. J. Pediatr. 1979; 95: 142
   PubMed Web of Science ®Google Scholar
• Zimmerman H. J., Ishak K. G. Valproate-induced hepatic injury: Analyses of 23 fatal cases. Hepatology 1982; 2: 591–597
   PubMed Web of Science ®Google Scholar
• Zafrani E. S., Berthelot P. Sodium valproate in the induction of unusual hepatotoxicity. Hepatology 1982; 2: 648–649
   PubMed Web of Science ®Google Scholar
• Loyning Y., Johannessen S. I., Ritland S., Strandjord R. E., Kloster R. Antiepileptic Therapy: Chronic Toxicity of Antiepileptic Drugs. Raven Press, New York 1983; 47
   Google Scholar
• Klaassen C. D. Absorption, distribution, and excretion of toxicants. Toxicology: The Basic Science of Poisons, L. J. Casarett, J. Doull. Macmillan, New York 1975; 31
   Google Scholar
• Roberts M. S., Anderson R. A., Moore D. E., Swarbrick J. The distribution of non-electrolytes between human stratum corneum and water. Aust. J. Pharm. Sci. 1977; 6: 77–82
   Google Scholar
• Tatken R. L., Lewis R. J. Registry of Toxic Effects of Chemical Substances. U.S. Dept. of Health and Human Services, Cincinnati, Ohio 1983; vol. 1: 193, 789, vol. 2, pp. 9, 884; vol. 3, pp. 248, 342
   Google Scholar
• Scott W. J., Nau H. Weak acids as human teratogens: Accumulation in the young mammalian embryo. Teratology 1985; 31: 25A
   Google Scholar
• Smith E. L., Hill R. L., Lehman I. R., Lefkowitz R. J., Handler P., White A. Principles of Biochemistry: General Aspects, 7th ed. McGraw-Hill, New York 1983; 519
   Google Scholar
• Brown N. A., Farmer P. B., Coakley M. Valproic acid teratogenicity: Demonstration that the biochemical mechanism differs from that of valproate hepatotoxicity. Biochem. Soc. Trans. 1985; 13: 75–77
   PubMed Web of Science ®Google Scholar
• Nau H. Valproic acid teratogenicity in mice after various administration and phenobarbital-pretreatment regimens: The parent drug and not one of the metabolites assayed is implicated as teratogen, Fund. Appl. Toxicol. 1986; 6: 662–668
   PubMedGoogle Scholar
• Lawley P. D. Carcinogenesis by alkylating agents. Chemical Carcinogens, C. E. Searle. American Chemical Society, Washington, DC 1976; 182–199
   Google Scholar
• Di Carlo F. J., Fung V. A. Summary of carcinogenicity data generated by the National Cancer Institute/ National Toxicology Program. Drug Metab. Rev. 1984; 15: 1251–1273
   PubMed Web of Science ®Google Scholar
• Lu A. Y. H., Coon M. J. Role of hemoprotein P-450 in fatty acid w-hydroxylation in a soluble enzyme system from liver microsomes. J. Biol. Chem. 1968; 243: 1329–1330
   PubMedGoogle Scholar
• Dickinson R. G., Hooper W. D., Eadie M. J. pH-Dependent rearrangement of the biosynthetic ester gluc-uronide of valproic acid to 6-glucuronidase-resistant forms. Drug Metab. Dispos. 1984; 12: 247–252
   PubMed Web of Science ®Google Scholar
• Dickinson R. G., Eadie M. J., Hooper W. D. Glucuronidase-resistant glucuronides of valproic acid: Consequences of enterohepatic recirculation of valproate in the rat. Biochem. Pharmacol. 1985; 34: 407–408
   Web of Science ®Google Scholar
• Faed E. M. Properties of acyl glucuronides: Implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab. Rev. 1984; 15: 1213–1249
   PubMed Web of Science ®Google Scholar
• Yonemoto J., Brown N. A., Webb M. Effects of di-methoxyethyl phthalate, monomethoxyethyl phthalate, 2-methoxyethanol and methoxyacetic acid on post implantation rat embryos in culture. Toxicol. Lett. 1984; 21: 97–102
   PubMed Web of Science ®Google Scholar
• Ritter E. J., Scott W. J., Jr., Randall J. L., Ritter J. M. Teratogenicity of dimethoxyethyl phthalate and metabolites methoxyethanol and methoxyacetic acid in the rat. Teratology 1985; 32: 25–31
   PubMedGoogle Scholar
• Rawlings S. J., Shuker D. E. G., Webb M., Brown N. A. The teratogenic potential of alkoxy acids in post-implantation rat embryo culture: Structure-activity relationships. Toxicol. Lett. 1985; 28: 49–58
   PubMed Web of Science ®Google Scholar
• Loscher W., Nau H., Marescaux C., Vergnes M. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy. Eur. J. Pharmacol. 1984; 99: 211–218
   PubMed Web of Science ®Google Scholar
• Glasgow A. M., Chase H. P. Production of features of Reye's syndrome in rats with 4-pentenoic acid. Pediatr. Res. 1975; 9: 133–138
   PubMed Web of Science ®Google Scholar
• Kesterson J. W., Granneman G. R., Machinist J. M. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984; 4: 1143–1152
   PubMed Web of Science ®Google Scholar
• Lewis J. H., Zimmerman H. J., Garrett C. T., Rosenberg E. Valproate-induced hepatic steatogenesis in rats. Hepatology 1982; 2: 870–873
   PubMed Web of Science ®Google Scholar
• Bressler R., Corredor C., Brendel K. Hypoglycin and hypoglycin-like compounds. Pharmacol. Rev. 1969; 21: 105–130
   PubMed Web of Science ®Google Scholar
• Lindhout D., Meinardi H. Spina bifida and in-utero exposure to valproate. Lancet 1984; 2: 396
   PubMed Web of Science ®Google Scholar
• Robert E., Kofkvist E., Mauguiere F. Valproate and spina bifida. Lancet 1984; 2: 1392
   PubMed Web of Science ®Google Scholar
• Tein I., Mac Gregor D. L. Possible valproate teratogenicity. Arch. Neurol. 1985; 42: 291–293
   PubMed Web of Science ®Google Scholar
• Mast T. J., Hendrickx A. G., Nau H. Teratology and pharmacokinetics of valproic acid in the rhesus monkey. Teratology 1985; 29: 47A
   Google Scholar
• Mast T. J., Cukierski M. A., Nau H., Hendrickx A. G. Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model. Toxicology, (in press)
   PubMed Web of Science ®Google Scholar
• Miyagawa A., Koyama K., Hara T., Imamura S., Ohguro T., Hatano H. Toxicity tests with sodium di-propyl acetate. Hofu Factory of Kyowa Fermentation Ind., Ltd. 1971, Report
   Google Scholar
• Whittle B. A. Pre-clinical teratological studies on sodium valproate (Epilim) and other anticonvulsants. Clinical and Pharmacological Aspects of Sodium Valproate (Epilim) in the Treatment of Epilepsy, N. J. Legg. Tunbridge Wells, NottinghamEngland 1976; 105–111, Proc. Symp.
   Google Scholar
• Petrere J. A., Wise L. D., Anderson J. A., Fitzgerald J. E., de la Iglesia F. A. Teratology study in rabbits with calcium valproate. Teratology 1984; 29: 50A
   Google Scholar
• Moffa A. M., White J. A., Mackay E. G., Frias J. L. Valproic acid, zinc and open neural tubes in 9-day-old hamster embryos. Teratology 1985; 29: 47A
   Google Scholar
• Ong L. L., Schardein J. L., Petrere J. A., Sakowski R., Jordan H., Humphrey R. R., Fitzgerald J. E., de la Iglesia F. A. Teratogenesis of calcium valproate in rats. Fund. Appl. Toxicol. 1983; 3: 121–126
   PubMedGoogle Scholar
• Ritter E. J., Scott W. J., Randall J. L. Teratogenicity and potentiation of phthalates and related alcohols and organic acids in Wistar rats. Teratology 1985; 29: 67A
   Google Scholar
• Lewandowski C., Klug S., Nau H., Neubert D. Pharmacokinetic aspects of drug effects in vitro: Effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture. Arch. Toxicol, (in press)
   Web of Science ®Google Scholar
• Rettenmeier A. W., Gordon W. P., Barnes H., Baillie T. A. Studies on the metabolic fate of valproic acid in the rat using stable isotope techniques. Xenobiotica, (in press)
   PubMed Web of Science ®Google Scholar
• Rettenmeier A. W., Gordon W. P., Prickett K. S., Levy R. H., Lockard J. S., Thummel K. E., Baillie T. A. Metabolic fate of valproic acid in the rhesus monkey: Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid. Drug Metab. Dispos. 1986; 14: 443–453
   PubMed Web of Science ®Google Scholar
• Rettenmeier A. W., Gordon W. P., Prickett K. S., Levy R. H., Baillie T. A. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid. Drug Metab. Dispos. 1986; 14: 454–464
   PubMed Web of Science ®Google Scholar
• Prickett K. S., Baillie T. A. Metabolism of unsaturated derivatives of valproic acid in rat liver microsomes and destruction of cytochrome P-450. Drug Metab. Dispos. 1986; 14: 221–229
   PubMed Web of Science ®Google Scholar